Retatrutide is a cutting-edge investigational peptide that functions as a triple agonist of GLP-1, GIP, and Glucagon receptors, making it one of the most promising therapies for significant and sustained fat loss. Unlike older GLP-1 agonists like Semaglutide, Retatrutide activates additional pathways that not only suppress appetite and improve insulin sensitivity but also increase energy expenditure and fat oxidation.

Benefits (Research Focus)

• Triple receptor agonism — studied for simultaneous activation of GLP-1, GIP, and Glucagon receptors
• Body composition research — investigated for fat-mass and lean-mass partitioning in DIO rodent models
• Glycemic endpoints — examined for fasting glucose and HbA1c parameters in T2D research models
• Energy expenditure — explored for glucagon-mediated thermogenic effects unique among incretin analogs
• Long-acting profile — C20 fatty diacid albumin-binding chemistry for extended half-life research

⚠️ Disclaimer

• This product is intended for laboratory research use only.
• Not for human or veterinary use.
• Not approved for diagnostic, therapeutic, or medical applications.
• Handle using appropriate laboratory safety procedures and personal protective equipment.